CA2054325C	Antisense oligonucleotides for treatment of cancer	RI.alpha. antisense oligonucleotides ana pharmaceutical compositions thereof are disclosed. Methods for treating certain cancers in animals comprising administering to animals an effective amount of an RI.alpha.antisense oligonucleotide, or a pharmaceutical composition thereof, are also disclosed.
CA2073500C	Compositions and methods for detecting and modulating rna activity and gene expression	This invention relates to materials and methods for detecting and modulating the activity of RNA. The invention generally relates to the field of "antisense" compounds, compounds which are capable of specific hybridization with a nucleotide sequence of an RNA. In accordance with preferred embodiments, this invention is directed to the design, synthesis and application of oligonucleotides and to methods for achieving therapeutic treatment of disease, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins and cleaving RNA in site specific fashions.  It is well known that most of the bodily states in mammals including most disease states, are effected by proteins. Such proteins, either acting directly or through their enzymatic functions, contribute in major proportion to many diseases in animals and man. Classical therapeutics has generally focused upon interactions with such proteins in efforts to moderate
CA2098842C	Use of host cell phospholipids for inhibiting microbial colonization	Compounds and compositions for the in vitro and in vivo inhibition of microbial colonization are provided. In particular, isolated host cell phospholipid molecules ("receptors"), and derivatives thereof, which bind microorganisms are disclosed.
CA2110291C	Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers	The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus, the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10 % by weight, may be used. In a more preferred embodiment, the average molecular weight is about 40,000 to 500,000 Daltons. The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The invention further provides compositions and methods to inhibit glial cell invasion, detrimental bone growth and neurite outgrowth. In a preferred embodiment, the inhibitory compositions further comprise an adhesive protein.
CA2113023C	Tnf receptor promoter	A promoter sequence of the human p55 TNF-R gene is provided. Also provided are sequence motifs and motif regions contained within the promoter sequence. Methods for preparing these motifs or motif regions and their use in the modulation of TNF function are also provided.
CA2117257C	Alginate-containing wound dressing	Disclosed is a wound dressing comprising an absorbent pad impregnated with an alginate for promoting wound healing and which upon contact with the wound will exhibit haemostatic properties, the absorbent pad being characterized as being soft and highly pliant,
CA2119782C	Carbamate analogs of thiaphysovenine, pharmaceutical compositions, and method for inhibiting cholinesterases	Substituted carbamates of tricyclic compounds which have a cyclic sulfer atom, having the formula:(See formula I) wherein R1 is H or a linear or branched chain C1- C10 alkyl group; and R2 is selected from the group consisting of a linear or branched chain -C1-C10 alkyl group, and (See formula I) wherein R3 and R4 are independently selected from the group consisting of H and a linear or branched chain C1-C10 -alkyl group;and with the proviso that when one of R1 or R2 is a H or a methyl group the other of R1 or R2 is not H and optical isomers of the 3aS series, provide highly potent and selective cholinergic agonist and blocking activity and are useful as pharmaceutical agents. Cholinergic disease are treated with these compounds such as glaucoma, Myasthenia Gravis, Alzheimer's disease. Methods for inhibiting esterases, acetylcholinesterase and butyryl-cholinesterase are also provided.
CA2120731C	Methods of improving allograft or xenograft tolerance by administration of an lfa-3 or cd2 binding protein	Methods of improving tolerance of transplanted xenograft tissue or allograft tissue in mammals, including humans, by the administration of LFA-3 or CD2 binding proteins.
CA2126091C	Novel biologically active polypeptides, preparation thereof and pharmaceutical composition containing said polypeptides	Novel biologically active polypeptides, preparation thereof and pharmaceutical compositions containing said polypeptides.
CA2129897C	Coa-it and paf inhibitors	Coenzyme A-independent transacylase is required for the release of free arachidonic acid and the production of arachidonic acid metabolites and platelet activation factor. Blocking of this enzyme inhibits the production of these inflammatory mediators and will be of therapeutic utility in a broad range of allergic and inflammatory diseases and disorders. Compounds are described herein which inhibit the action of CoA-IT and are therefore useful in the treatment of disease states caused thereby. The figure shows the effect of compound three on CoA-IT activity. In one embodiment, the compound is of formula (I)
CA2133439C	Compounds useful for treating allergic and inflammatory diseases	Novel compounds of formula (I) are described herein. These compounds inhibit the production of Tumor Necrosis Factor and are useful in the treatment of disease states mediated or exacerbated by TNF production. The compounds of the present invention are also useful in the mediation or inhibition of enzymatic or catalytic activity of phosphodiesterase IV and are therefore useful in the treatment of disease states in need of mediation or inhibition thereof.
CA2137764C	Pharmaceutical compositions comprising solutions or dispersions of a staurosporine active ingredient in a saturated polyalkylene glycol glyceride	A pharmaceutical composition comprising a solution or dispersion of a staurosporine active ingredient in a saturated polyalkylene glycol glyceride such as a mixture of esters of C8-C18 saturated fatty acids with glycerol and polyethylene glycol. The composition may be administered in capsules or as a dispersion in an aqueous medium. The pharmaceutical composition may be used as an orally administrable form of a staurosporine active ingredient.
CA2144312C	Unsaturated aliphatic dicarboxylic acids	Disclosed are certain novel polyunsaturated dioic acids having between 8 and 16 carbon atoms (inclusive), excluding those compounds in the group consisting of: 2,5 octadienedioic acid; 1,7 octadienedioic acid; 2,4,6 octatrienedioic acid; and 1,3,5,7 nonatetraenedioic acid; 2,5,8 decatrienedioic acid; 3,6 dodecadienedioic acid; 3,13 hexadecadienedioic acid. Also disclosed are pharmaceutical or cosmetic compositions comprising unsaturated dioic acids and certain of their derivatives. Also disclosed are methods of treating human skin and a method of preparing unsaturated dioic acids.
CA2153849C	Method for improving breeding activity of boars by using feed for the breeding boars	This invention aims at improving the breeding activity of boars, especially at preventing the reduction of fertilization capacity in the hot season, more particularly, this invention provides a method for improving the breeding activity of boars with the use of a feed for breeding boars which contains saccharides mainly composed of oligosaccharides.
CA2155014C	Process for the preparation of baccatin iii analogs bearing new c2 and c4 functional groups	Process for the preparation of a derivative or analog of baccatin III or 10-desacetyl baccatin III having a C2 substituent other than benzoate and/or a C4 substituent other than acetate in which the C2 benzoate substituent and/or the C4 acetate substituent of a derivative of baccatin III or 10-desacetyl baccatin III is/are selectively reduced or hydrolyzed to the corresponding hydroxy group(s) and converted to R31COO- and/or R30COO-, respectively, wherein R30 and R31 are independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, monocyclic aryl or monocyclic heteroaryl.
CA2156289C	Drug composition containing nucleic acid copolymer	This invention has for its object to insure an effective utilization of single-stranded nucleic acid copolymers, particularly poly(adenylic acid-uridylic acid), and to provide a pharmaceutical composition having antitumor activity.      The invention typically relates to a pharmaceutical composition comprising a lipid device such as Lipofectin (trademark), 3-O-(4-dimethylaminobutanoyl)-1,2-O-dioleylgycerol, 3-O-(2-dimethylamino-ethyl)carbamoyl-1,2-O-dioleylglycerol, 3-O-(2-diethylaminoethyl) carbamoyl-1,2-O-dioleylgycerol, or 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoylglycerol and poly(adenylic acid-uridylic acid).
CA2157128C	Camptothecin derivatives, preparations thereof and antitumor agents	New camptothecin derivatives of the general formula (1), preparations thereof and antitumor agents comprising the same, (see formula 1) wherein R1 represents a hydrogen atom or a C1-C6 alkyl group, R2 represents a hydrogen or a C1-C6 alkoxy group, R3 represents a hydrogen or halogen atom or a C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, C2-C6 acyloxy or methoxyethoxymethoxy group, R4 represents a hydrogen or halogen atom, and R5 represents a C1-C6 alkyl, C3-C6 unsaturated alkyl, alkylthioalkyl, alkoxyalkyl, pyridyl or substituted phenyl group, with the proviso that all of the R2, R3 and R4 substituents should not be a hydrogen atom.
CA2157590C	Use of terbinafine for the therapeutic treatment of pneumocystosis	Use of terbinafine for the primary and secondary prophylaxis and treatment of Pneumocystis carinii pneumonia, including the oral administration of terbinafine 3-20 mg/kg/day to a subject suffering from this type of pneumonia.
CA2157792C	N-(3-piperidinyl-carbonyl)-beta-alanine derivatives as paf antagonists	This invention relates to .beta.-alanine derivatives represented by formula (I), wherein each symbol is as defined in the specification and pharmaceutically acceptable salt thereof which is glycoprotein IIb/IIIa antagonist, inhibitor of blood platelets aggregation and inhibitor of the binding of fibrinogen to blood platelets, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment of diseases indicated in the specification to a human being or an animal.
CA2158610C	17-deoxycorticosteroid-21-/o/-carboxylic esters, processes for their preparation and pharmaceuticals containing these compounds	17-Deoxycorticoid-21-carboxylic esters of the formula I (see Formula I) are described, in which A is CHOH and CHCl, CH2, C=O or 9(11) double bond; Y is H, F or Cl; Z is H, F or CH3; R(1) is aryl or hetaryl and R(2) is H or methyl. They are obtained by reacting a compound of the formula II, (see formula II) in which R(4) is OH, with an activated carboxylic acid of the formula III, R(5)-CO-[(C1-C4)-alkyl]-R(1) III. The compounds I possess very strong local and topical antiinflammatory activity and exhibit a very good ratio of local to systemic antiinflammatory effect, which ratio is often clearly superior to that of structurally related corticoid 21-esters which do not carry any aryl or hetaryl group in the 21-ester residue or to that of analogous 17-deoxycorticoids having an unesterified, that is a free, 21-hydroxyl group.
CA2168021C	Vasoconstrictive dihydrobenzopyran derivatives	The present invention is concerned with compounds of formula (I), the pharmaceuticaliy acceptable acid addition salts thereof, and the stereochemically isomeric forms thereof, wherein R1 is hydrogen or C1-6alkyl; R2 is hydrogen or C1-6alkyl; R3 is hydrogen or C1-6alkyl; R4 is hydrogen, halo, C1-6alkyl, hydroxy, C1-5alkyloxy, aryloxy or arylmethoxy; R5 and R6 designate R5a and R6a, wherein R5a and R6a taken together form a bivalent radical; or R5 and R6 can designate R5b and R6b, wherein R5b is hydrogen and R6b is a heterocycle or an optionally substitued alkenyl or alkynyl group; or R5 and R6 designate R5c and R6c, wherein R5c and R6c are hydrogen, halo, C1-6alkyl, C3-6alkenyl; C3-6alkynyl, hydroxy, C1-6alkyloxy, cyano, aminoC1-6alkyl, carboxyl, C1-6alkyloxycarbonyl, nitro, amino, aminocarbonyl, C1-6alkylcarbonylamino, or mono-di(C1-6alkyl)amino; Q is a heterocyclic ring containing at least one nitrogen atom or a radical of formula (aa), pharmaceutical compositions, preparations and use as a medicine are also described.
CA2168447C	Compounds and methods for inhibition of hiv and related viruses	The present invention is directed to compounds, compositions and methods of inhibiting and treating HIV and related viruses, and methods for cocrystallizing reverse transcriptase in vitro, inhibition of the replication of HIV and related viruses thereof.
CA2173208C	Levobupivacaine useful for managing chronic pain	Levobupivacaine is useful for managing chronic pain.
CA2173839C	Transferrin compositions to alleviate the side effects of cytotoxic drugs	The invention pertains to a eutrophic drug composition containing transferrins, particularly human transferrin. It allows the toxic effects of cytotoxic drugs when used at high dosages or over prolonged times, e.g., cyclosporin, to be alleviated or even suppressed.
CA2175372C	Novel 9-hydroxy-pyrido[1,2-a]pyrimidin-4-one ether derivatives	The present invention is concerned with novel compounds having formula (I), the pharmaceutically acceptable acid addition salts thereof and the stereo-chemically isomeric forms thereof, their use as a medicine, wherein Alk represents C1-4alkanediyl; Dis a bicyclic heterocycle of formula (a) or (b) wherein each R1 independently is C2-6alkenyl; C2-6alkynyl; C3-6cycloalkyl optionally substituted with C1-4alkyl; C1-19alkyl optionally substituted with C3-6cycloalkyl, halo, C1-6alkyloxy or cyano; and each R2 independently is hydrogen or C1-4alkyl. Novel compounds; compositions; processes for preparing novel compounds and intermediates are described.
CA2176181C	D4t polymorphic form i process	The present invention concerns a novel process using controlled cooling for obtaining d4T polymorphic Form I from a mixture containing one or more of polymorphic Forms I, II and III.     Compound d4T has been approved for use in the treatment of AIDS.
CA2177961C	Use of dimeticone for treating aphthae and stomatitis	The invention disclosed relates to treating aphthae and stomatitis by applying dimeticone to the afflicted oral mucosa.
CA2180660C	Novel piperidine derivatives with paf antagonist activity	Compounds of general formula (I) and their salts and solvates are PAF antagonists and as such are useful in the treatment of various diseases or disorders mediated by PAF. Pharmaceutical compositions including these compounds and processes for their preparation are also provided.
CA2182620C	Improving glucose tolerance	A compound of formula (I) or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride optionally in the form of its monohydrate) is used for improving the glucose tolerance of humans having impaired glucose tolerance or non-insulin dependent diabetes mellitus.
CA2183549C	Acidified nitrite as an antimicrobial agent	The invention relates to the use of acidified nitrite  as an antimicrobial agent and describes a dosage form for use in the treatment of bacterial, viral or fungal conditions.  The dosage form may be in any pharmaceutically  acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. Amongst the many potential applications for the invention,  the inventive  composition has been shown to be particularly effective as an animal feed supplement, and as an agent for sterilising objects.  Compositions and methods of use for these applications are described.
CA2187449C	Anti-cancer compounds containing cyclopentaquinazoline ring	Cyclopentaquinazoline of formula (I), wherein R1 is hydrogen, amino, C1-4 alkyl, C1-4 alkoxy, C1-4 hydroxyalkyl or C1-4 fluoroalkyl; wherein R2 is hydrogen, C1-4 alkyl, C3-4 alkenyl, C3-4 alkynyl, C2-4 hydroxyalkyl, C2-4 halogenoalkyl or C1-4 cyanoalkyl; Ar1 is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, C1-4 alkyl and C1-4 alkoxy; and wherein R3 is a group of the formula: -A1-Ar2-A2-Y1, in which A1 is a bond between the .alpha.-carbon atom of the group -CONHCH(CO2H)- and Ar2 or is a C1-2 alkylene group; Ar2 is phenylene, tetrazoldiyl, tiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which in the case of phenylene may optionally bear one or two substituents on the ring selected from halogeno, nitro, C1-4 alkyl and C1-4 alkoxy; A2 is a C1-3 alkylene or C2-3 alkenylene group; and a pharmaceutically acceptable salt or ester thereof are of therapeutic value particularly in the treatment of cancer.
CA2202503C	Modified polyunsaturated fatty acids	The present invention provides polyunsaturated fatty acid compounds having antimalarial and/or neutrophil stimulatory activity. The polyunsaturated fatty acids contain 18-25 carbons and 1-6 double bonds and are characterized in that they have one or two substitutions selected from the group consisting of .beta. oxa, .gamma. oxa, .beta. thia and .gamma. thia. It is also preferred that the polyunsaturated fatty acid compound includes a further substitution selected from the group consisting of hydroxy, hydroperoxy, peroxy, carboxymethyl substitutions or attached to an amino acid. The invention also provides a method of producing an unsaturated oxa substituted fatty acid comprising reacting an unsaturated fatty acid alcohol with a carbene that is inserted in the OH bond of the alcohol. The invention further provides a method of treating inflammation with a composition comprising at least one hydroxy, hydroperoxy or peroxy derivative of a polyunsaturated fatty acid having a C18-24 carbon chain and 1-6 cis or trans double bonds.
CA2203237C	Aminotetrazole derivatives useful as nitric oxide synthase inhibitors	Compounds having formula (I) and pharmaceutically acceptable salts thereof, wherein B is NR5R11, wherein R5 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkynyl and aryl, and R11 is selected from a 3 to 8 member heterocyclyl radical in which at least one member of the ring is carbon and in which 1 to about 4 members are heteroatoms independently selected from oxygen, nitrogen and sulfur and said heterocyclyl radical may be optionally substituted, useful as nitric oxide synthase inhibitors.
CA2205573C	Enterokinetic benzamide	The present invention is concerned with a novel benzamide derivative of formula (I). Pharmaceutical compositions comprising said novel compounds processes for preparing compounds and compositions, and the use thereof as a medicine, in particular in the treatment of conditions involving a decreased motility of the intestine are described.
CA2207503C	Use of aminopurine antiviral agents for the treatment and prophylaxis of latent herpesvirus infections	A method for the treatment of latent infection of herpes viruses in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of a compound of formula (A) or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing.
CA2207804C	Amides of mono and bicarboxylic acids with amino acids or glycosamines, selectively active on the cannabinoid peripheral receptor	The present invention relates to amides of formula (I):    wherein R1 is an optionally substituted linear or branched hydrocarbon radical, or a group of formula (II) or (III):    wherein R4 is an optionally substituted linear hydrocarbon radical, R7 is H or a linear or branched alkyl, and the residues   are glycosaminic residues; a pharmaceutical composition comprising the amide; and a use of the amide as a CB2 receptor modulator.
CA2209360C	Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen	This invention provides compositions derived from the sequences encoding the variable light and/or variable heavy regions of monoclonal anti-idiotype antibody 3H1 and methods for using these compositions.
CA2210022C	Paroxetine hydrochloride solvates	The present invention relates to paroxetine hydrochloride anhydrate (see formula I) substantially free of bound propan 2-ol, several forms of the above, processes for preparing the above, new intermediates useful in preparing the above and methods of treating and/or preventing certain diseases by administering the compounds of the invention to a sufferer in need thereof.
CA2213842C	Use of dextromethorphan or dextrorphan for the treatment of urinary incontinence	Urinary incontenence is alleviated in a mammal by administering to the mammal a urinary incontinence alleviating amount of dextromethorphan, dextrorphan, their mixtures and/or pharmaceutically acceptable salts, alone or in combination with a pharmacologically active agent such as an anticholinergic sympathomimetic, tricyclic antidepressant, antispasmodic, direct-acting smooth muscle relaxant, estrogen, compound having estrogen-like activity, or any combination of the foregoing.
CA2217479C	Derivatives of phenoxyethylamine having a high affinity for 5-ht1a receptor, their preparation procedure, their application as medications and pharmaceutical compounds containing them	Phenoxyethylamine derivatives of general formula (I) having high affinity for  the 5-HT1Areceptor, methods for preparing same, pharmaceutical compositions containing said derivatives, and their use, in particular as gastric acid secretion inhibitors or as antiemetics, are disclosed. In general formula(I), Ar is phenyl substituted by one or more substituents; and R is a C1-1- hydrocarbon radical selected from straight or branched alkyl, alkenyl or alkynyl radicals, saturated or unsaturated mono-or polycyclic cycloalkyl, cycloalkylalkyl or alkylcycloalkyl radicals; a pyridyl or isoquinolyl radical, phenyl optionally substituted by one or more substituent, and salts thereof.
CA2224176C	Gene transfer for treating a connective tissue of a mammalian host	The subject invention concerns a method of introducing at least one DNA sequence expressing a protein or protein fragment which substantially alleviates articular cartilage defects. This methods involves in vitro culture of chondrocytes, transfection of the chondrocytes with a recombinant vector housing the DNA sequence to be expressed, and delivery of the transfected chondrocytes to the damaged cartilage region. This method can also be used in tandem with synovial cell delivery techniques of the present invention. This method is also useful as a model in animal studies regarding joint pathologies.
CA2224269C	Compressed dry-granulation desogestrel tablets	The invention concerns compressed dry-granulation tablets or granules comprising desogestrel obtainable by roller compaction or by slugging, which can be prepared by a method of production, whereby desogestrel, optionally together with other active compounds and/or excipients, in a first step of the process is compressed by applying elevated pressure, and thereafter in a second step is crushed into particles, after which in a third step the particles may be processed into tablets or filled into capsules, using methods known in the art.
CA2231545C	Oral gel capsule formulation of 1,2,4-benzotriazine oxides	Disclosed are anticancer tumor soft gelatin capsules comprising a 1,2,4-benzotriazine oxide and an oily excipient selected from the group consisting of soybean oil and fractionated coconut oil.
CA2232222C	Treatment of hiv positive patients	A mixture of betasitosterol and betasitosteryl glycoside in a ratio of between 1:1 and 500:1 is administered to an HIV infected individual. This has the effect of stabilizing CD4 cell numbers, decreases the plasma viral load, degree of apoptosis in, and the serum levels of 1 L6 in the peripheral blood.
CA2233620C	Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies as antiinflammatory agents	A method of using pyrazolyl benzenesulfonamide compounds in treating inflammation and inflammation-related disorders in animals.
CA2240494C	Therapeutic molecules generated by trans-splicing	The molecules and methods of the present invention provide a means for in vivo production of a therapeutic molecule in a selected subset of cells. The pre-therapeutic molecules of the invention are substrates for a trans-splicing reaction between the pre-therapeutic molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides an active therapeutic RNA which is functional as RNA or encodes a protein to be expressed in the target cells. The expression product of the mRNAis a protein of therapeutic value to the cell or a toxin which causes killing of the specific cells.
CA2243708C	Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection	Use of an antibacterial system comprising lactoperoxidase and a peroxide donor for preparing a preparation for prophylactic of therapeutic treatment "in vivo" of an infection caused by the bacteria Helicobacter pylori existing in the oral cavity, in the throat and in the stomach which preparation is completed by the presence of thiocyanate in an antibacterial level, and eventually in the presence of lactoferrin. A daily dose for human treatment is 1.2-1.6 gram of the system taken 3 times a day.
CA2246760C	Polysaccharide-peptide-conjugates	The invention relates to a polysaccharide-peptide conjugate wherein the polysaccharide is advantageously immunogenic, which comprises a polysaccharide chain composed of repeat units and a plurality of peptide moieties, each moiety containing a cysteine residue and being covalently attached at random along the polysaccharide chain, through an indirect bound involving the thiol group of the cysteine residue and an amino, hydroxyl or carboxyl group of the polysaccharide, said indirect bound being achieved through either a linker or a spacer-linker moiety provided that the spacer entity of the spacer-linker moiety is linked to the amino, hydroxyl or carboxyl group of the polysaccharide. To this end, a useful linker may be e.g., N-(.gamma.-maleimidobutyryloxy) succinimide ester. Such a conjugate may typically exhibit a "Rake" configuration. Conjugation processes are also disclosed. Conjugates of the invention are in particular useful in the vaccinal field to elicit a protective long term immune response against a pathogenic microorganism from which the immunogenic polysaccharide is derived.
CA2250630C	Novel lantibiotic related to actagardine, and processes for the preparation and use thereof	The present invention relates to a novel lantibiotic having the formula NH2-R-actagardine, where NH2-R is the radical of the amino acid alanine, which is formed by the microorganism Actinoplanes liguriae, DSM 11797 or Actinoplanes garbadiensis, DSM 11796 during fermentation, chemical derivatives of the lantibiotic, a process for its preparation and the use of the lantibiotics as pharmaceuticals.
CA2250712C	Chimeric isoprenoid synthases and uses thereof	Disclosed is a chimeric isoprenoid synthase polypeptide including a first domain from a first isoprenoid synthase joined to a second domain from a second, heterologous isoprenoid synthase, whereby the chimeric isoprenoid synthase is capable of catalyzing the production of isoprenoid reaction products that are not produced in the absence of the second domain of the second, heterologous isoprenoid synthase. Also disclosed is a chimeric isoprenoid synthase polypeptide including an asymmetrically positioned homologous domain, whereby the chimeric isoprenoid synthase is capable of catalyzing the production of isoprenoid reaction products that are not produced when the domain is positioned at its naturally-occurring site in the isoprenoid synthase polypeptide.
CA2251949C	Use of lofexidine in the manufacture of a medicament for treating attention deficit hyperactive disorder	The invention relates to the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Lofexidine is used for control of ADHD.     Typical doses are from 0.005 to 0.02 mg/kg.
CA2252050C	Buccal, non-polar spray or capsule	A buccal aerosol spray or capsule using a non-polar solvent has now been developed which provides biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal aerosol spray of the invention comprises formulation (I): propellant 50-95 %, non-polar solvent 5-50 %, active compound 0.0025- 40 %, flavoring agent 0.05-5 %. The soft bite gelatin capsule of the invention comprises formulation (II): non-polar solvent 30-99.8 %, emulsifier 0-20 %, active compound 0.0003-32 %, and flavoring agent 0.05-60.
CA2252986C	Process for preparing functional recombinant tissue factor	The present invention relates to a process for preparing functional recombinant tissue factor in a prokaryotic host organism.
CA2253130C	A medicament for treating obesity and improving lipid metabolism	A medicament for preventive and therapeutic treatment of obesity and a disease with abnormal lipid metabolism which comprises as an active ingredient a compound selected from the group consisting of 24-alkylcholestan-3-ones and 24- alkylcholesten-3-ones such as 24-alkylcholestan-3-ones, 24-alkylcholestmonoen- 3-ones, 24-alkylcholestdien-3-ones, 24-alkylcholesttrien-3-ones and 24- alkylcholesttetraen-3- ones. 26
CA2253207C	Growth inhibition and eradication of solid tumors using neuroendocrine resetting therapy and photodynamic therapy	A method of ablating the growth of or eradicating tumors in mammals having prolactin, growth hormone, and melatonin daily rhythms by adjusting one or more of the prolactin, growth hormone, and melatonin profiles of the mammal to conform to or approach the corresponding normal profile for healthy members of the same species and sex as said mammal, contacting the cells of the tumor with a photoactive photosensitizer, and, exposing the photosensitizer-contact tumor cells to light of a predetermined wavelength, power density, and energy level.
CA2254759C	Inhibitors of prenyl transferases	A family of compounds capable of inhibiting the activity of prenyl transferases. The compounds are covered by one of the two formulas (I) and (II). Each of the R groups is defined in the disclosure.
CA2255804C	Antitumoral method by administration of partricin derivatives	The use of some semisynthetic derivatives of the antifungal polyene partricin to selectively hinder the growth of tumor cells is here described. Their use can be associated with the use of other known antineoplastic agents, in particular in the cases where a resistance to these agents is present or has developed. The invention can be applied to systems of cell cultures as well as to the therapeutic practice.
CA2256633C	Selected derivatives of k-252a	Disclosed herein are selected indolocarbazole derivatives which are represented by general formula (I). The compounds are useful for enhancing the function and/or survival of a trophic factor responsive cell. They inhibit interleukin-2 production and have immunosuppressive activity.
CA2257810C	Skin wash composition comprising an .alpha.-hydroxy acid or other acid and a detergent base	A skin wash composition intended for topical application to water-wetted skin comprising an .alpha.-hydroxy acid active ingredient formulated in a mild and non-irritant detergent base consisting of a mixture of a non-ionic alkylpolyglucoside surfactant and an amphoteric surfactant.
CA2261923C	Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists	Pyridyl-phtalazin diones having formula (I), wherein R1 and R2 are selected from the group consisting of hydrogen, halogen, and methoxy or wherein R1 and R2 together form methylenedioxy, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing an effective glycines antagonistic amount thereof, are useful in combatting neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission in a living animal, including a human, in need thereof.
CA2268968C	Iminochlorin aspartic acid derivatives	The present invention provides an iminochlorin aspartic acid derivative represented by the following formula (I):(see formula I) Wherein Asp represents an aspartic acid residue, or a pharmaceutically acceptable salt thereof. The compound of the present invention is useful as a photosensitizer for photophysico-chemical diagnosis and therapy of cancer, because it has a high accumulability to cancerous cells, reactivity to external energy and a cancerous cell destroying effect which is effective even againt cancers developing in deep site, while it is rapidly excreted from normal cells and therefore causes no damage thereto.
CA2270952C	New use for 1,3-propanediol derivatives	Use of a compound of formula (I) wherein R1 is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and each of R2, R3, R4 and R5, independently, is H or lower alkyl, in free form or in pharmaceutically acceptable salt form, in the prevention or treatment of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or of acute rejection in a xenograft transplant recipient.
CA2274591C	Benzothiophenecarboxamide derivatives and pgd2 antagonists comprising them	A compound, a pharmaceutically acceptable salt thereof, or a hydrate thereof having PGD2-antagonistic activities, inhibitory activities against infiltration of eosinophils, and being useful as a drug for treating diseases, such as systemic mastocytosis and disorder of systemic mast cell activation, as well as tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, ischemic reperfusion injury, inflammation and atopic dermatitis , which is shown by formula (I), is provided.
CA2276442C	Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients	A method of administering iron to dialysis patients is accomplished by infusion of a noncolloidal ferric compound, soluble in hemodialysis or peritoneal dialysis solutions, by the process of dialysis. A pharmaceutical composition is provided consisting essentially of dialysis solution including a soluble noncolloidal ferric compound, preferably ferric pyrophosphate.
CA2279063C	A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal	Pharmaceutical compositions for the treatment of diseases involving cognitive dysfunction in a mammal comprising an estrogen agonist or antagonist or a pharmaceutically acceptable salt thereof; an acetyl cholinesterase inhibitor or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The estrogen agonists or antagonists and acetylcholinesterase inhibitors are present in amounts that render the composition effective in the treatment of diseases of cognitive dysfunction including Alzheimer's Disease and Dementia. The method of using these composition is also disclosed. The compositions may help memory inhancement.
CA2280612C	Amino acid-sugar composition	An amino acid-sugar composition comprising an amino acid composition which comprises proline, alanine, glycine, valine, threonine, leucine, histidine, lysine, isoleucine, arginine, phenylalanine, tyrosine, and tryptophan; and sugar of trehalose. The amino acid-sugar composition has effects of compensating the reduction of the blood level of amino acids associated with severe exercise, of improving the exercise, of reducing the degree of fatigue after exercise and of recovering from fatigue. In addition, the administration of the composition permits the inhibition of the consumption of amino acids associated with exercise and any induction of fatigue accompanied by exercise.
CA2281918C	Oxazolidines as 5-ht2a-antagonists	The invention relates to novel oxazolidine derivatives of formula (I), wherein R1, R2 and R3 have the meaning cited in Claim 1. The invention further relates to the salts thereof and to a method for the production of the inventive compounds. The compounds of formula (I) act as 5-HT2A antagonists having a reuptake-inhibiting, antidepressant or anxiolytic effect and can be used in the production of medicaments.
CA2284774C	Theobromine antitussive compositions	The invention relates to the use of theobromine and/or its salts and/or its complexes optionally in admixture with other known active ingredients and inert, solid or liquid carriers, additives and auxiliary agents for the manufacture of a pharmaceutical composition suitable for relieving cough syndrome. Further subject of the invention is a method of treatment of a human or animal subject being in a condition where relieving of cough is desirable which comprises the step of administering in an effective amount theobromine and/or its salts and/or its complexes optionally in admixture with other known active ingredients and suitable inert, solid or liquid carriers, additives and auxiliary agents.
CA2288024C	Compositions comprising condensation polymer of an aromatic sulfonic acid and an aldehyde for preventing pregnancy	This invention pertains to the discovery that condensation polymers of an aldehyde and aromatic sulfonic acids and fractions thereof, such as formaldehyde naphthalenesulfonic acid condensation polymers, can prevent pregnancy in an individual.
CA2290893C	Magnesium omeprazole	Improved process to produce magnesium omeprazole substantially amorphous with pharmaceutically acceptable low level of methanol and solid pharmaceutical compositions.
CA2292586C	Solid pharmaceutical dosage forms in form of a particulate dispersion	Solid particulate dispersions of pharmaceutical agents in a matrix of a water-soluble polymer exhibiting good aqueous dissolution enhanced bioavailability. The method of the invention utilizes water-soluble polymers such as polyvinylpyrrolidone, hydroxypropyl cellulose or hydroxypropylmethyl cellulose as carriers. The invention provides for mixing or extracting the active ingredients in solid particulate form with the polymeric carrier at a temperature at which the polymer softens, or even melts, but the drug remains solid or crystalline. The drug particules thus become coated and produce a product that is matrix coated, i.e. a particulate dispersion.
CA2292846C	Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them	The invention relates to LH-RH peptide analogues with excellent affinity for LH-RH receptors, of formula (I): A1-A2-A3-A4-A5-A6-HAA-A7-Pro-Z in which Z, A1 to A7 are specified in the description and HAA is a non-aromatic hydrophobic amino acid having from 7 to 20 carbon atoms. The invention also relates to the uses of said peptide analogues and to the pharmaceutical compositions containing them.
CA2297198C	Macrocyclic lactones, compositions, and methods of use	The present invention provides a compound of formula (I), wherein R1 and R2 are the same or different and are independently H, C1-C6 straight-chain or branched-chain saturated or unsaturated alkyl, aryl, R6CH2-, R6CO-, or R6SO2-, wherein R6 is H, C1-C6 straight-chain or branched-chain saturated or unsaturated alkyl, or aryl; R3 is H, C1-C6 straight-chain or branched-chain saturated alkyl, aryl, an oxime, or an oxime methyl ether; at least one aromatic ring position is optionally substituted with a substituent selected from the group consisting of halo, nitro, amino, hydroxyl, thio, acyl, C1-C6 alkyl, and cyano; and Z is a contiguous linker comprising a chain of 7-10 atoms (including heteroatoms) which atoms, together with the five atoms beginning with the carbon of the aromatic ring in meta-relationship with OR1 and ending with the carbon directly attached to the alkyl oxygen of the lactone, which carbons are covalently bonded to either end of linker Z, integrally form a 12-15 membered ring; or a pharmaceutically acceptable salt, an ester, or a prodrug thereof. The present invention further provides a pharmaceutical composition, and a method of preventing or treating cancer, using at least one compound of the present invention, optionally in conjunction with an additional compound other than a compound of the present invention.
CA2297959C	Use of erythropoietin and iron preparations for the production of pharmaceutical combination preparations for the treatment of rheumatic diseases	The present invention is concerned with the use of individual administration forms of an erythropoietin preparation and a physiologically compatible iron preparation corresponding to an equivalent amount of 1-40 mg of iron ions for the production of a pharmaceutical combination preparation for the treatment of rheumatic diseases.
CA2298445C	Method and compositions for treating late phase allergic reactions and inflammatory diseases	A method of treating a mammalian patient suffering from or prone to a condition characterized by late phase allergic reactions, airway hyperresponsiveness or inflammatory reactions, e.g., asthma, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, inflammatory bowel disease or rheumatoid arthritis, comprising the administration to the patient of an oral, parenteral, intrabronchial, topical, intranasal or intraocular pharmaceutical composition containing in each dose about 0.005 to about 1.0 mg per kilogram of patient body weight of ultra-low molecular weight heparins (ULMWH) or other sulfated polysaccharides having average molecular weights of about 1,000-3,000 daltons. Suitable inhalant and other pharmaceutical compositions for use in the novel treatment method are also disclosed.
CA2303448C	Specific steady-state r-type ca2+ channel blockers and use thereof	The present invention relates to Ca2+ channel blockers and more particularly to the R-type Ca2+ channel blockers. More specifically, the invention relates to Ca2+ channel blockers activity of Mandevilla velutina and Mandevilla illustris. The present invention further concerns saponin-like compounds isolated from Mandevilla species. The present invention also relates to the treatment of several pathologies that involve the nifedipine-insensitive but isradipine sensitive steady-state R-type Ca2+ channel and the use of steady-state R-type Ca2+ channel blockers in the treatment of these pathologies.
CA2304821C	Osteoblast-specific mitogens and drugs containing such compounds	The invention is directed to compounds of formula (I) wherein R1 - alkyl, alkenyl or alkynyl having from 6 to 24 carbon atoms; n = 0 - 12; X = oxygen or NH; and the physiologically safe salts, esters, optically active forms, racemates and derivatives thereof which can be metabolized in vivo to yield compounds of general formula (I), methods of preparing same, and drugs containing said compounds, for treating bone metabolic disorders.
CA2306837C	Treatment of female sexual dysfunction	Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others. The formulations are also useful for preventing the occurrence of yeast infections, improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. A clitoral drug delivery device is also provided.
CA2310230C	The use of brinzolamide to prevent visual field loss	Methods for preventing or slowing visual field loss are disclosed.
CA2311734C	Flash-melt oral dosage formulation	There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.
CA2312990C	Novel salts of metformin and method	Novel salts of the antidiabetic agent metformin are provided which are metformin salts of dibasic acids (2:1 molar ratio), preferably metformin (2:1) fumarate and metformin (2:1) succinate, which may be employed alone or in combination with another antihyperglycemic agent such as glyburide, for treating diabetes. A method for treating diabetes employing the novel metformin salt by itself or in combination with another antidiabetic agent is also provided.
CA2313878C	Composition for suppressing behavior problems of pets	A composition for suppressing behavior problems of pets, comprising theanine, and optionally one or more compounds selected from the group consisting of highly unsaturated fatty acids and cholines; and a method of suppressing behavior problems of pets, comprising administering the above composition to a pet having behavior problems. The composition can be effectively used for suppressing various behavior problems associated with the pet.
CA2314170C	Method of the prophylactic treatment of mastitis	A method of prophylactic treatment of mastitis in mammalian, including human, mothers, is described. The method comprises administration of a prophylactically effective dosage of a human or veterinary medicament containing at least one type of xanthophylls, such as astaxanthin, to said mothers. Preferably, the astaxanthin exists in a form esterified with fatty acids, e.g. in the form of algae meal produced by culturing of the alga Haematococcus sp. Further, use of at least one type of xanthophylls, such as astaxanthin, for the preparation of a human or veterinary medicament for the prophylactic treatment of mastitis in mammalian, including human, mothers is disclosed.
CA2314326C	Transdermal therapeutic device and method with capsaicin and capsaicin analogs	Transdermal application of capsaicin (or a capsaicin analog) in a concentration from greater than about 5 % to about 10 % by weight has been discovered to be an extremely effective therapy for treating neuropathic pain, so long as an anesthetic, preferably by means of a transdermal patch, is administered initially to the affected area to minimize the expected side effects from subsequent capsaicin application.
CA2315693C	Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases	Methods are provided for treating proliferative diseases, especially cancers, comprising administering (1) a famesyl protein transferase inhibitor in conjunction with (2) an antineoplastic agent and/or radiation therapy.
CA2316356C	Benzoxazine compounds for enhancing synaptic response	Compounds of the structure shown below, having a certain benzoxazine ring system and their precursors are disclosed which are useful for enhancing synaptic responses mediated by AMPA receptors. Also disclosed are methods for preparing such compounds, and methods for their use in treating subjects suffering from impaired nervous or intellectual functioning due to deficiencies in the number of excitatory synapses or in the number of AMPA receptors. The invention compounds can also be used for the treatment of non-impaired subjects for enhancing performance in sensory-motor and cognitive tasks which depend on brain networks utilizing AMPA receptors and for improving memory encoding. (see formula 1) or (see formula 2)
CA2319836C	Hydroxylation activated prodrugs	The present invention concerns enzymatic aromatic hydroxylation-activated prodrugs, particularly and-tumour prodrugs and those which are specifically activated by the hydroxylation activity of the enzyme CYP1B1.
CA2320822C	Substituted isoindolones and their use as cyclic gmp modulators in medicaments	The invention relates to substituted isoindolon derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6 and R7 have the meanings cited in the description. Said derivatives represent valuable active substances in medicaments for the therapy and prophylaxis of diseases, e.g. cardiovascular diseases such a hypertension, angina pectoris, heart failures, thrombosis or atherosclerosis. The compounds of formula (I) are capable of modulating endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of pathological states associated with disorders of the cGMP metabolism. The invention also relates to a method for the production of compounds of formula (I), their use in the therapy and prophylaxis of the above-mentioned pathological states and in the production of medicaments for such states. The invention further relates to pharmaceutical preparations containing the compounds of formula (I).
CA2323536C	Pharmaceutical formulation comprising a 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity and a process for the preparation of such formulation	Oral pharmaceutical formulation comprising granules having an inert core coated with a layer, comprising a 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity, a disintegrant and a surfactant in a matrix of a melt coating substance essentially consisting of one or more esters of glycerol and fatty acids, a separating layer and an enteric coating layer, and a process for the preparation of such formulation using a melt coating technique for the preparation of the benzimidazole containing layer.
CA2324343C	C11 oxymyl and hydroxylamino prostaglandins useful as medicaments	The invention provides novel prostaglandin analogs. In particular, the present invention relates to compounds having a structure according to formula (I): (see formula I) wherein R1, R2, R3, R4, R5, R6, W, X, Z, a, b, and p are defined below. This invention also includes optical isomers, diastereomers and enantiomers of the formula, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders and glaucoma using these compounds or the compositions containing them.
CA2326048C	Peroral active agent suspension	The present invention relates to orally administered suspensions of pharmaceutical active substances of the NSAID type, particularly the antirheumatic agent meloxicam, which are stabilised by the addition of small amounts of highly dispersed silicon dioxide using high shear forces and adding small amounts of hydrophilic polymers to form a three-dimensional siloid structure, and a process for the preparation thereof.
CA2336628C	Method for reducing the damaging effects of radiation therapy on animal skin and mucosa	The severity of damage caused to the skin and mucosa of animals with cancer undergoing radiation therapy is mitigated by feeding the animal a nutritionally balanced food composition containing omega-6 polyunsaturated fatty acids which are supplemented with a mixture of an omega-3 polyunsaturated fatty acids and arginine.
CA2338901C	Prevention of migraine recurrence	The invention relates to the use of eletriptan, or a pharmaceutically acceptable salt or composition thereof, for the manufacture of a medicament for the prevention of migraine recurrence and to the use of a 5-HT1B/1D receptor agonist, or a pharmaceutically acceptable salt or composition thereof, for the manufacture of a dual-, sustained-, delayed-, controlled- or pulsed-release pharmaceutical composition for the prevention of migraine recurrence.
CA2339411C	Engraftable human neural stem cells	Stable clones of neural stem cells (NSCs) have been isolated from human fetal telencephalon. In vitro, these self-renewing clones can spontaneously give rise to all three fundamental neural cell types (neurons, oligodendrocytes and astrocytes). Following transplantation into germinal zones of the developing newborn mouse brain, these NSCs, like their rodent counterparts can participate in aspects of normal development. These include migration along well-established migratory pathways to disseminated CNS regions, differentiation into developmentally and regionally appropriate cell types in response to microenvironmental cues and non-disruptive, non-tumorigenic interspersion with host progenitors.
CA2339630C	Carboline derivatives as cgmp phosphodiesterase inhibitors	Compounds of general structural formula (I) wherein A represents a 5- or 6-membered heteroaryl group containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulphur; and use of the compounds and salts and solvates thereof, as therapeutic agents are disclosed.In particular, the invention relates to carboline derivatives which are potent and selective inhibitors of cGMP-specific PDE.
CA2340545C	Chelate compound-containing antibacterial agent for helicobacter pylori	An antibacterial agent is provided, which has an action for inhibiting growth of Helicobacter pylori participating to occurrence of chronic gastritis and gastric ulcer, and a highly safe substance is used as an effective component therein. An antibacterial agent for Helicobacter pylori is characterized in that at least one substance selected from the group consisting of ethylenediaminetetraacetic acid and its metal salts is contained as an effective component.
CA2340898C	Compositions and methods for treating intracellular infections	A method of treating or preventing an intracellular infection in an animal comprising administering a first effective amount of a suitable drug contained in first biocompatible microspheres that have a diameter of less than or equal to about 10 microns, wherein the first microspheres release the suitable drug upon administration at a first effective rate. A second set of microspheres greater than 10 microns in diameter may also be administered to provide continuing systemic release of the drug.
CA2340921C	Use of taxanes to treat brain cancer	The present invention relates to a new use of taxoid derivatives. It relates more precisely to a method for treating abnormal cell proliferation in the brain of mammals including men by administrating a taxoid derivative.
CA2343414C	Fc receptor modulators and uses thereof	This invention relates to a pharmaceutical composition comprising a Fc receptor modulating compound and a pharmaceutically acceptable carrier. The present invention also relates to a method for treating a variety of diseases using a Fc receptor modulating compound.
CA2344248C	4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors	Cholesteryl ester transfer protein inhibitors, of the Formula (I), prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
CA2344652C	Carboxymethylgalactose derivatives	Carboxymethylgalactose derivatives represented by general formula (1);    and salts thereof, which exhibit reactivity to selectins and are useful as inhibitors against selectin-related diseases such as various inflammations and cancerous metastasis; In said formula, R is a group represented by formula (1a), (1b) or (1c).
CA2348390C	Compositions for the treatment and prevention of neurological and pathopsychological diseases	Compositions comprising one or more active ingredients and, optionally, one or more nutritional substances, solid, liquid and/or semiliquid excipients or auxiliaries, wherein the active ingredients consist of a) a component A consisting of one or more phosphatidylserines, b) a component B consisting of one or more methyl transporters, and c) a component C consisting of one or more compounds selected from methyl and methylene donors, provided that phosphatidylserines and compounds with methyl transporting properties do not form part of component C are well-suited for the treatment and prevention of transmethylation disorders, preferably neurological and pathopsychological diseases.
CA2348767C	Method for producing an antitumoral agent and antitumoral agent thus obtained	In order to lower the painfulness of injection of the remedy containing the products of Iignin basic hydrolysis and oxidation, pyrophosphate, NaCl and water the value of pH of the remedy is adjusted to a neutral one by the addition of HCl.
CA2351617C	Method for inhibiting dental resorptive lesions	The present invention relates to a method for inhibiting dental resorptive lesions and other disease states associated with dental resorptive lesions in a mammal by administering a therapeutically effective amount of a bisphosphonate or a pharmaceutically acceptable salt thereof to a mammal in need thereof. This invention also relates to methods of alleviating of pain and reducing the risk of tooth loss associated with dental resorptive lesions in mammals.
CA2352946C	Baby food stimulating growth of the thymus	A thymus growth stimulating baby food is provided, substantially composed of a fat component, as well as a carbohydrate component and a protein component of animal or vegetable or animal and vegetable but not human origin, whereby the protein component is composed of intact proteins, hydrolyzed proteins, peptides or the constituents thereof, or of amino acids or a mixture thereof not bound to peptides or proteins. This type of baby food is characterized in that the total amount of arginine is at least 3.7 g per 100 g of the amino acids present in toto, and that it contains zinc (calculated as elementary zinc) in an amount of at least 40 mg per 100 g of the amino acids present in toto.
CA2355712C	Antiviral nucleoside analogues	In accordance with the present invention there is provided a nucleoside analogue of formula (I) or (Ia) which is useful as an antiviral agent.
CA2360677C	Anticonvulsant derivatives useful in treating bulimia nervosa	Anticonvulsant derivatives of formula: (I), wherein x is CH2 oroxygen, for treating bulimia nervosa are disclosed.
CA2371517C	An improving agent for hypoalbuminaemia	The present invention is to offer a hydantoin derivative useful as a therapeutic agent for hypoalbuminaemia with high safety.  This invention relates to an improving agent for hypoalbuminaemia containing a hydantoin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient. (see formula I) [In the formula, each of R1 and R2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, a hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group.]  It is apparent from the above-mentioned clinical test that the administration of the compound of the present invention gave an increase of serum albumin value of patients suffering from hypoalbuminaemia and, therefore, an improving effect of the compound of the present invention for hypoalbuminaemia was shown. Consequently, the compounds of the present invention are very useful as a therapeutic agent for hypoalbuminaemia.
CA2382631C	Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids	A compound comprising a poly(ether-thioether), poly(ether-sulfoxide) or poly(ether-sulfone) backbone bearing a plurality of ligands that are individually bound to chiral carbon atoms located within the backbone, at least one of the ligands includ-ing a moiety such as a naturally occurring nucleobase, a nucleobase binding group or a DNA interchelator; a process of synthesizing the compound, monomers to be used in this process and their synthesis process and processes for using the compound in biochem-istry and medicine.
CA2383054C	Polyhydroxyalkanoate compositions for soft tissue repair, augmentation, and viscosupplementation	Polyhydroxyalkanoate materials are provided which are suitable for repair of soft tissue, augmentation, and as visco-supplements in animals, particularly humans. The materials comprise liquid polyhydroxyalkanoate polymer compositions or poly-hydroxyalkanoate microdispersions. Devices also are provided for storage and delivery of the polyhydroxyalkanoate compositions in vivo. Methods are provided for repairing or augmenting soft tissue in animals using the materials. In a preferred embodiment, the method includes the steps of (a) selecting the animal soft tissue to be repaired or augmented; and (b) placing an injectable, liquid polyhydroxyalkanoate polymer or a polyhydroxyalkanoate microdispersion into the animal soft tissue, preferably using a minimally-invasive method such as injection. In another embodiment, the liquid polyhydroxyalkanoate polymer compositions or polyhydroxyalkanoate microdispersions are used as viscosupplements.
CA2386817C	The use of baclofen in the treatment of alcoholism	The use of baclofen for the treatment of alcohol withdrawal syndrome and promotion of abstinence in alcoholics.
CA2387351C	Indole derivatives as tyrosine kinase inhibitors	The present invention relates to compounds of Formula I which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.(see formula I)
CA2390858C	N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of      factor xa	This invention is directed to a compound of formula (I) which is useful for inhibiting the activity of Factor Xa, by contacting said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of formula (I), methods for their preparation, their use, such as in inhibit-ing the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detri-mental excess amount of thrombin.
CA2393344C	Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof	A method of improving bioavailability of ergot derivatives administered using sustained-release delivery systems includes combining an ergot derivative or mixture thereof with a pharmaceutically acceptable hydrophilic swelling agent or mixture thereof and one or more pharmaceutically acceptable excipients. The bioavailability of sustained-release formulations of the present invention is at least equal to the bioavailability of the ergot derivative or mixture thereof administered using a conventional delivery system. Sustained-release compositions that improve bioavailability are also provided. Methods and compositions according to the present invention may provide sustained-release characteristics while improving the bioavailability of ergot derivatives.
CA2395016C	Treatment of dna viral infections	The synergistic combination of a loop diuretic and a cardiac glycoside is useful in the treatment of DNA viral infec-tions.
CA2395226C	Devices for the delivery of drugs having antiprogestinic properties	This invention relates to a device for the controlled release over a prolonged period of time of a drug having an-tiprogestinic properties, said device comprising - a core comprising said drug,- optionally a membrane encasing said core, wherein said core and/or membrane is made of a siloxane-based elastomer composition comprising at least one elastomer and possibly a non-crosslinked polymer. The device is characterized in that - the elastomer composition comprises poly(alkylene oxide) groups and that the poly(alkylene oxide) groups are present in the elastomer or polymer as alkoxy-terminated grafts of polysiloxane units, or as blocks, the said grafts or blocks being linked to the polysiloxane units by silicon-carbon bonds, or as a mixture of these forms.
CA2395881C	Inhalation particles	A method for preparing particles suitable for pulmonary drug delivery by inhalation, and inhalation compositions comprising such particles are provided. The method comprises providing a liquid feed stock comprising one or several active agents, atomising the liquid feed stock, suspending the droplets in a carrier gas, and passing the carrier gas and droplets through a heated tube flow reactor under predetermined residence time and temperature history, and collecting the particles produced. Fine uniform crystalline spherical uncharged particles with narrow aerodynamic particle size distribution between about 1 to 5 m and rough surfaces, are obtained. The particles show improved dispersibility and stability.
CA2397593C	Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one	The invention relates to a pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5, 7--dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one hydrochloride, a method of making the same, a pharmaceutical composition and its use for treating cancer and inhibiting protein kinases or cyclin dependant kinases in a patient.
CA2398389C	Method for inhibiting a tumor	A method for inhibiting a tumor in a mammal using a composition comprising an anthocyanin or cyanidin from a berry is described. The method involves using the composition in an amount and for a time to inhibit the tumor. The composition can include other antitumor agents.
CA2399405C	5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents	The invention concerns compositions that contain 5-aminolevulinic acid or/and derivatives thereof dissolved or dispersed in a non-aqueous liquid. The invention in particular concerns a two-chamber system which contains compositions of 5-aminolevulinic acid and/or derivatives thereof in which the active substances are located in a non-aqueous phase and which are ready-to-use after mixing with an aqueous phase.
CA2400737C	Nutritional formulation containing prebiotic substances	A nutritional composition is provided which comprises oligofructose and sialyllactose.
CA2401424C	Alprazolam inclusion complexes and pharmaceutical compositions thereof	Pharmaceutical composition for transmucosal delivery contains an inclusion complex of alprazolam and a water soluble unsubstituted or substituted beta- or gamma-cyclodextrin such as 2-hydroxypropyl beta-cyclodextrin, and a pharmaceutically acceptable carrier therefor. The pharmaceutical composition is of particular application in the treatment of Generalised Anxiety Disorder or for the management of panic disorders.
CA2403026C	Process for the preparation of 6-o-propargyl erythromycin derivatives	Disclosed herein is a process for the preparation of erythromycin derivatives, or pharmaceutically acceptable salts thereof, which contain an optionally substituted propargyl group at the 6-O-position.
CA2404688C	Nuclear factor .kappa.b inducing factor	The present invention is directed to nuclear factor kB (NFkB)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NKkB. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NFkB induction in a patient, methods and compositions for lowering NFkB induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treament and/or prevention of an NFkB-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
CA2407806C	Use of heparin or nonanticoagulant heparin for inhibiting apoptosis arising from ischemia perfusion injury	Heparin reduces ischemia-reperfusion injury to myocardium. This effect has been attributed complement inhibition, but heparin also has other activities that might diminish ischemia-reperfusion. To further probe these mechanisms, we compared heparin and an O-desulfated nonanticoagulant heparin with greatly reduced anti-complement activity. Given at the time of coronary artery reperfusion in a canine model of myocardial infarction, both heparin and O-desulfated heparin equally reduced neutrophil adherence to ischemic-reperfused coronary artery endothelium, influx of neutrophils into ischemic-reperfused myocardium, myocardial necrosis and release of creatine kinase into plasma. Heparin and O-desulfated heparin also prevented dysfunction of endothelial-dependent coronary relaxation following ischemic injury. In addition, heparin and O-desulfated heparin inhibited translocation of the transcription factor NF-.KAPPA.B from cytoplasm to the nucleus in human endothelial cells and decreased NF-.KAPPA.B DNA binding in human endothelium and ischemic-reperfused rat myocardium. Thus, heparin and nonanticoagulant heparin decrease ischemia-reperfusion injury by disrupting multiple levels of the inflammatory cascade, including the novel observation that heparins inhibit activation of the pro-inflammatory transcription factor NF-.KAPPA.B.
CA2410526C	Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds	The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.
CA2411818C	Cyclopentabenzofuran compounds and uses thereof	The invention provides compounds having a cyclopentabenzofuran core comprising a group of formula (ii): (see formula ii) attached via an oxygen atom to a cyclopentabenzofuran core of formula (i): (see formula i) compositions comprising said compounds and therapeutic uses of the compounds and compositions for treating a cancer or a cancerous condition or a disease state or condition associated with cellular hyperproliferation.
CA2412941C	Piperidine compounds for use as ccr-3 inhibitors	Compounds of formula (I) in free or salt form, where Ar1 is phenyl substituted by one or more halogen atoms, Ar2 is phenyl or naphthyl which is unsubstituted or substituted by one or more substituents selected from halogen, cyano, hydroxy, nitro, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy or C1-C8-alkoxycarbonyl, R1 is hydrogen or C1-C8-alkyl optionally substituted by hydroxy, C1-C8-alkoxy, acyloxy, N(R2)R3, halogen, carboxy, C1-C8-alkoxycarbonyl, -CON(R4)R5 or by a monovalent cyclic organic group, R2 and R3 are each independently hydrogen or C1-C8-alkyl, or R2 is hydrogen and R3 is acyl or -SO2R6, or R2 and R3 together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, R4 and R5 are each independently hydrogen or C1-C8-alkyl, or R4 and R5 together with the nitrogen atom to which they are attached denote a 5- 6-membered heterocyclic group, R6 is C1-C8-alkyl, C1-C8-haloalkyl, or phenyl optionally substituted by C1-C8-alkyl, and n is 1, 2, 3, or 4, with the proviso that when Ar1 is p-chlorophenyl and R1 is hydrogen, Ar2 is not phenyl or p-nitrophenyl. The compounds are useful as pharmaceuticals.
CA2416512C	Enhancement of the action of anti-infective agents	The invention provided a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the group comprising antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, characterised in that the agent is formulated with an administration medium which comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which administration medium includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5w3], decosahexaenoic acid [C22: 60], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide.
CA2426348C	Retrovirus isolated from humans	The present invention comprises spumavirus isolated from humans. More specifically, the spumavirus of the present invention was isolated from humans who had exposure to nonhuman primates. Importantly, the spumavirus of the present invention or antibodies to the spumavirus can be used to detect the presence of spumavirus or antibodies in body fluids, for pathogenicity studies of related viruses, and as a vector for gene therapies. The spumavirus of the invention can also be used for treatment of conditions in humans due to the presence of rapidly dividing cells and for recombinant live virus vaccination.
CA2434393C	Heparin with average molecular mass	The invention relates to a novel heparin having an average molecular weight within a range of from 10 to 11.5 kd, in particular, an average molecular weight of 10 kd. Said heparin is obtained by controlled depolymerization of unfractionated heparin and subsequent molecular filtration. Said heparin is used for the preparation of a medicament for the prophylaxis and therapy of thrombo-embolic processes and, inter alia, for the inhibition of coagulation in extracorporeal circulations.
CA2436764C	Rehydration composition	The invention relates to a fluid that can be used for preventing or treating hypohydration and the secondary consequences thereof. The fluid comprises one or more carbohydrates and minerals and is further characterized by a low osmolarity. The invention further relates to the use of such a fluid for medical, dietetic and other applications.
CA2437603C	Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid	Degradation of a Lewis acid by a quantity of sevoflurane is provided by combining the quantity of sevoflurane with a Lewis acid inhibitor, for example, water, butylated hydroxytoluene, methylparaben, propylparben, propofol and thymol. A method of the invention involves a method for storing a quantity of sevoflurane, the method comprising the steps of providing a container defining an interior space, the container having an interior wall adjacent the interior space defined by the container; providing a quantity of sevoflurane; coating the interior wall of the container with the Lewis acid inhibitor; placing the quantity of sevoflurane in the interior space defined by the container.
CA2438813C	Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as ip antagonists	This invention relates to compounds which are IP receptor antagonists and which are represented by the general formula (1) wherein G2 is a heteroaryl group containing one or two nitrogen atoms and substituted with a carboxylic acid group, and G1 is as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, their use as therapeutic agents, and methods of preparation thereof.
CA2441235C	Aryl and biaryl compounds having mch modulatory activity	In one embodiment, this invention provides a novel class of compounds as antagonists of the MCH receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration or one or more of diseases associated with the MCH receptor. An illustrative inventive compound is shown here.
CA2442151C	Stable solution of reduced coenzyme q	The present invention provides a composition of a practically usable solution capable of stably maintaining, against oxidation, reduced coenzyme Q, which has not been employed in practice so far because of being liable to undergo oxidation and hydrophobic, a method of preparing the solution and a method of storing the solution. A solution of reduced coenzyme Q which can be stored at a low temperature or room temperature over a long time can be prepared by coating reduced coenzyme Q with liposome made of refined soybean lecithin, etc, and solubilizing, or solubilizing or emulsifying reduced coenzyme Q by using a surfactant at a low temperature.
CA2443543C	Supplementation of equine feedstuffs	The present invention provides equine feedstuffs and methods by which plasma glutamine concentrations in equine animals can be increased or maintained. The present invention provides equine feedstuffs with supplemented glutamine and with optional high levels of fat or oil. Glutamine supplementation provides a pharmacological benefit to the equine animal, for example in respect of one or more or over-training, infection, surgery, other stressful conditions or catabolic stress.
CA2455064C	Transdermal therapeutic system based on polyacrylate contact adhesives without functional groups	The invention relates to a transdermal therapeutic system (TTS) consisting of a rear layer, a protective layer and an active-substance-containing polymer layer. The polymer matrix comprises a polyacrylate which contains an extremely reduced number of functional groups. In one particular embodiment, the polyacrylate is free from hydroxyl groups and/or carboxyl groups.
CA2459033C	Methods for inhibiting cognitive deterioration in adults with down's syndrome	This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can be used in methods for preventing or reversing cognitive deterioration in adults with Down's syndrome. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for preventing or reversing cognitive deterioration in a DS patient including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
CA2460135C	Use of pyridazinone compounds as phosphodiesterase iv inhibitors for treating cancer and other diseases	The invention relates to the use of Phosphodiesterase IV inhibitors and/or the physiologically acceptable salts thereof in the production of a medicament for the treatment of osteoporosis, tumors, tumor metastases, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, ulzerative colitis and AIDS.
CA2464309C	Combinations comprising a selective cyclooxygenase-2 inhibitor	A combination therapy for treating patients suffering from pre-malignant colon lesions (e.g. polyps) and colon cancer, as well as other malignancies, is disclosed. The patient is treated concurrently with a cycloocygenase-2 inhibitor and at least one compound selected from the group consisting of a microtubule interfering agent, an epithelial growth factor receptor tyrosine protein kinase inhibitor and a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
CA2464777C	Method of suppressing the germination of candida albicans using whey-derived free fatty acids	Several studies have demonstrated that bovine whey produced by cheese maker industry contains several bioactive factors promoting health and preventing disease. Although many efforts have been made over the years to show that immunoglobulins, lactoperoxidase, lactoferrin, lysosyme and small peptides present in whey have antimicrobial activities against several pathogenic microorganisms, such activity has not been investigated so far for the lipid fraction of whey. There, is disclosed a method of inhibiting the germination of Candida albicans using free fatty acids derived from whey cream. Further fractionation by HPLC demonstrates that this activity can be mainly attributed to lauric, myristoleic, linoleic and arachidonic acids.
CA2467329A1	Inner core lps epitopes and uses thereof	The subject invention provides vaccines, vaccine components, and uses thereof suitable for providing immunity involving B-cell activating molecules derived from veterinary bacterial pathogens lipopolysaccharide (LPS), said molecules comprising one or more epitopes of the inner-core oligosaccharide portion of the lipopolysaccharide having the structure:    A Figure 1 Where R and R' are variable outer care structures.
CA2468374C	Glp-1 derivatives	Derivatives of GLP-1 and analogues thereof having a lipophilic substituent have interesting pharmacological properties, in particular they have a more protracted profile of action than GLP-1(7-37).
CA2471147C	Nitric oxide donors for treatment of disease and injury	A method of promoting neurogenesis by administering a therapeutic amount of a phosphodiesterase inhibitor compound to a patient in need of neurogenesis promotion. A compound for providing neurogenesis having an effective amount of a phosphodiesterase inhibitor sufficient to promote neurogenesis. A phosphodiesterase inhibitor for promoting neurogenesis. A method of augmenting the production of brain cells and facilitating cellular structural and receptor changes by administering an effective amount of a phosphodiesterase inhibitor compound to a site in need of augmentation. A method of increasing both neurological and cognitive function by administering an effective amount of a phosphodiesterase inhibitor compound to a patient.
CA2474904C	Once-a-day oxycodone formulations	The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodoen ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
CA2475224C	Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides	The addition of low concentrations of combinations of water-soluble organic salts of zinc to gels, creams, lotions or ointments can increase the ability of these products to reduce or prevent exogenous irritants from causing irritation of the underlying substrate. The addition of low concentrations of combinations of water-soluble organic zinc salts to these gels, creams, lotions or ointments also can reduce the irritation of skin or mucous membranes caused by the addition of potentially-irritating substances such as spermicides, microbicides, fungicides or other therapeutic agents to the gel, cream, lotion or ointment. The advantages of this anti-irritant approach over others, which generally employ high concentrations of single zinc salts, are the reduced potential for zinc toxicity, the reduced potential for toxicity related to zinc itself, and the preservation of the desirable biological properties of potentially-irritating therapeutic substances added to the gel, cream, lotion or ointment.
CA2492874C	Taste masked oral composition of telithromycin	Composition for oral administration of telithromycin comprising : spherical agglomerates of telithromycin ; ethylcellulose ; an acrylic polymer ; anti-agglomeration agentwhere the composition is in the form of microcapsules having a 2 layers coating.
CA2497725C	Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)	The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R1,R2 and R3 have the definitions given in the description.
CA2516078C	Catechol compositions and use thereof	Novel quinone and catechol compositions, compositions containing prodrugs of quinone and catechol compositions, and method of use for the treatment of solid tumor cancers and other vascular proliferative disorders. The disclosure particulary relates to the discovery of dual activity agents capable of generating both a vascular targeting effect and direct tumor cell cytotoxicity in order to achieve an enhanced anti-tumor response in a patient. In one aspect there is disclosed a compound comprising a structure of:(see above formula)
CA2526954C	Antibiotics containing bone substitute material with sustained active substance release	Antibiotics containing bone substitute material is described which is characterized in that it is composed of a compacted mixture of granules of calcium sulfate dihydrate, calcium carbonate and at least one representative of the aminoglycoside antibiotics, lincosamide antibiotics, glycopeptide antibiotics, macrolide antibiotics, ketolide antibiotics, the nitroimidazoles, the fluorochinolone antibiotics and the oxazolidinone antibiotics, the steroid antibiotics, the antiseptic agents and the fungicidal/fungistatic antibiotics which are partly or entirely sheathed with a layer of glycerol tripalmitate and/or glycerol tristearate and/or glycerol trilaurate and/or 1-hexadecyl alcohol which connects the granules with each other.
CA2530543C	Illudin analogs as anti-tumor agents	A compound having the structure   wherein R = methyl or hydroxyl; and R1, R2 and R3 = methyl or alkyl.    A compound having the structure   wherein R = H or methyl; R1, R2 and R3 = methyl or alkyl; and R ~ H, when R1, R2 and R3 = methyl.
CA2536321A1	Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents	The invention relates to compounds represented by Formula (I):, and to prodrugs thereof, pharmaceutically salts or solvates of said compounds or said prodrugs, wherein each of X1-X5 and R1-R5 are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).
CA2545543A1	Novel use of peptide compounds for treating central neuropathic pain	The present invention concerns the use of peptide compounds for treating central neuropathic pain.
CA2547080A1	Heterocyclic protein kinase inhibitors and uses thereof	Described herein are compounds that are useful as protein kinase inhibitors of formula (I) or a pharmaceutically acceptable salt thereof, wherein Ring B, Z1, Z2, U, p, Q, R1, R2, R3, and R3 are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplantation.
CA2547887C	Protein modifier production inhibitor	The compounds, at least in selected embodiments, are suitable as inhibitors of the formation of protein modification products capable of inhibiting vitamin B6 deficiency disease as a side effect, especially as a renal protective agent. There is provided a use, as an active ingredient, of any of free or salt-form compounds of either of the formulae: (I) or (II), wherein R1 is substituted or unsubstituted aromatic ring; and each of R2, R3 and R4 is a hydrogen atom or monovalent organic group, or alternatively R2 and R3 cooperate to form a condensed ring or R3 and R4 cooperate to represent a divalent organic group, provided that R3 and R4 are not simultaneously hydrogen atoms.(see formula I) (see formula II)
CA2548922A1	2- ( (2, 3-dihydroxypropyl) aminomethyl) chromane derivatives for use as beta-3 adrenoreceptor agonists in the treatment of urological and inflammatory disorders	This invention relates to chroman derivatives of formula (I) and salts thereof which are useful as active ingredients of pharmaceutical preparations. The chroman derivatives of the present invention have an excellent activity as BETA 3 antagonists and are useful for the prophylaxis and treatment of diseases associated with BETA 3 activity, in particular for the treatment of urological disorder or disease, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; and inflammatory disorders, such as asthma and COPD.
CA2553816A1	Di-steroidal prodrugs of ethinyl estradiol	The present invention is a di-steroidal prodrug of ethinyl estradiol according to formula (I)
CA2554073A1	1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of movement disorders	The invention relates to a novel use of known 1-[2H-1-benzopyran-2-one-8-yl]~piperazine derivatives, broad spectrum 5-HT receptor binding compounds, having amongst other functional serotonin receptor activities, potent 5-HT1A receptor agonistic activity, 5-HT1D receptor antagonistic activity and 5-HT7 receptor agonistic activity. The compounds of the invention are useful for the preparation of medicaments for treating, ameliorating or preventing movement disorders. The invention relates to compounds of the general formula (1) (1) wherein the symbols have the meanings as given in the description.
CA2555406A1	Improved therapy using a combination of raloxifene and alendronate	Provided are methods of treating bone disease including, but not limited to, osteoporosis, metastatic bone disease, or Paget~s disease, by administering a combination of raloxifene and alendronate in a manner that mitigates the formation of ulcerative adverse events.
CA2558019A1	Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics	Compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6 and X are as defined herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammtory, allergic, or proliferative processes in a patient using these compounds.
CA2558160A1	Antisense oligonucleotides for treatment of muscle wasting	The invention provides compositions of oligonucleotides targeted at genes involved in muscle wasting and/or muscle growth. In some embodiments, the oligonucleotides are modified. In some embodiments, the compositions contain one, or more than one, oligonucleotide. The invention also provides methods and kits using the compositions of the invention for the treatment of muscle wasting conditions and/or the promotion of muscle growth.
CA2562821A1	Composition and method for raising blood glucose level	Composition and method of administering the composition to oral mucosa, to raise the blood glucose (sugar) level of an individual. The composition comprises: a. an effective amount of glucose, b. an effective amount of at least one absorption enhancer chosen from lecithin, hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening primrose oil, menthol, trihydroxy oxo cholanyl glycine, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers, polidocanol alkyl ethers, chenodeoxycholate, deoxycholate, alkali metal salicylate, pharmaceutically acceptable edetate, and pharmaceutically acceptable salts and analogues thereof, and c. an effective amount of a pharmaceutically acceptable carrier, wherein the composition is free of any active pharmaceutical agents. Also disclosed are non-aerosol dispensers containing and for use in administering the composition, and the use of the composition to raise blood glucose levels, to treat hypoglycemia or low blood sugar, or in the manufacture of a product to treat hypoglycemia or low blood sugar.
CA2567916C	Method for producing antibiotic / antibiotics - particles and their use	A method for producing antibiotic / antibiotics-particles characterized in that an aqueous solution of an amino glycoside-antibiotic or an aqueous solution comprising two or more amino glyco-side-antibiotics is mixed under agitation with a solvent mixture comprising isopropanol and at least one additional alcohol, with the volume ratio of the solvent mixture to the aqueous solution being at least 3 to 1 and with the suspension developed being agitated until the primarily yielded coarse antibiotic / antibiotics aggregates disintegrate into particles, which have a grain size smaller than 400 m.
CA2574518A1	Pharmaceutical composition and non dependence coffee comprising edible carboxylic acid and/or its acid salt and coffeine	Pharmaceutical composition and food comprising edible carboxylic acid and/or its acid salt and optionally coffeine, crude drug and pharmaceutical acceptable carrier are disclosed. The invention also discloses the use and method of the composition or food. The composition or food of the present invention can prevent, treat or relief allergy, ache, cold, viral infection, thrombus or clotting, inflammation, cancer, intoxication, memory decay, coffeine dependence. The invention also relates to feedstuff for animals.
CA2582559A1	Treatment of hpv infections and cancer	The present invention concerns the use of agents that inhibit the chymotryptic activity of the 26s unit of the proteosome for the prevention of infection by, or to effect elimination of, human papilloma virus (HPV) from tissues of subjects infected with, or susceptible to, such viruses. The agents are particularly useful for preventing the development of cancers caused by HPV.
CA2583392A1	Imidazole derivatives as vanilloid receptor ligands	Therapeutic benzimidazoles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.
CA2583658A1	Multi-carotenoids compositions and uses therefor	A stable nutritional supplement composition for oral administration comprising about 71% by weight, of a tomato extract containing therein at least 2% to 10% by weight of lycopene, 0.25% to 2% by weight of phytoene, and 0.2% to 2% by weight of phytofluene, and about 29% by weight, of a suitable encapsulating matrix. A suitable encapsulating matrix is an edible oil exemplified by soya oil, pumpkin seed oil, grape-seed oil and the like. The tomato extract may additionally comprise one or more of at least one carotene selected from the group comprising .beta.-carotene, .gamma.- carotene, and .delta.-carotene, a phytosterol, a tocopheral and a phospholipid. The tomato extract may be further processed into oleoresin emulsions, or into beadlets, or into dry powders. Methods for ameliorating the effects of aging-related urinary tract malfunctions in men, comprising orally administrating on a regular basis, an effective amount of the nutritional supplement compositions disclosed herein.
CA2585967A1	Substituted indolizines and derivatives as cns agents	Compounds of formula (I) of pharmaceutically acceptable salts thereof are provided: formula (I), which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.
CA2591917C	Analgesic compositions for treating painful conditions of the anal region and uses thereof	Analgesic composition and use thereof for treating painful conditions of the body and of the anorectal region. The composition comprises a combination of nitroglycerin and sucralfate, and may further comprise lidocaine. The composition may be included in a petrolatum base along with a water soluble lubricant. These compositions have been found effective in treating painful conditions in the anal region such as anal fissure, inflamed or recently thrombosed hemorrhoids, ligation of internal hemorrhoids or of the chronic anal pains.
CA2597616A1	Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives	The present invention provides cycloalkylfused indole, benzothiophene, benzofuran, and indene derivatives, and methods for using them to, for example, treat, prevent and/or ameliorate central nervous system diseases by antagonizing 5-HT1A receptors and modulating serotonin levels.
CA2598948A1	Enhanced formulations of lamotrigine	A once-a-day, extended-release formulation of lamotrigine, exhibiting a significantly similar release rate throughout the GI tract irrespective of the pH of the environment, is provided. The formulation comprises lamotrigine, an organic acid, a release enhancing polymer and a release controlling polymer. The use of the formulation for the treatment of the neurological disorders is also disclosed.
CA2603030A1	Benzyloxypropylamine derivative	Disclosed is a novel benzyloxypropylamine derivative having an excellent tachykinin receptor antagonistic effect. This compound shows a good transfer into the blood and a long blood half-life in the blood kinetic test using a guinea pig orally administered with the compound and is stable in an animal plasma. The compound also shows a high transfer to the central nervous system when it is orally administered to a guinea pig at a certain dose. Accordingly, the benzyloxypropylamine derivative is quite useful as a novel anti-tachykinin agent.
CA2603199A1	Shigella ipad protein and its use as a vaccine against shigella infection	The present invention relates to compositions and methods for blocking entry of Shigella into a cell of an animal, to therefore providing protection against, or reduce the severity of Shigella infections. More particularly it relates to the use of the IpaD protein obtained from natural sources and/or through synthesis or recombinant technology, and conjugates thereof to induce neutralizing antibodies having protective activity against several serotypes of Shigella, in particular S. flexneri. The composition of the invention is useful to prevent and/or treat shigellosis caused by a bacterium of the Shigella family.
CA2604161A1	Purine and imidazopyridine derivatives for immunosuppression	The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas ( I ) and ( II ).
CA2604515A1	Toll-like receptor 14 (tlr14 ) and use thereof	An isolated polypeptide comprises an amino acid sequence of SEQ ID No. 1 or 2 or a variant or fragment thereof. The variant may comprise an amino acid sequence that is at least 70% or 95% identical to the amino acid sequence of SEQ ID No. 1 or 2. A fragment thereof may be a peptide comprising at least 12 contiguous amino acids of SEQ ID No. 1 or 2. The polypeptide exhibits toll-like receptor activity. The TLR has been named TLRl 4. TLR receptors recognise a range of ligands and activate a series of signalling pathways that lead to the induction of immune and inflammatory genes.
CA2611715C	Methods and systems for neural maintenance and regeneration	Methods and systems are described that release one or both of a neurotrophin and an inhibitor of the degradation of the neurotrophin within or in the vicinity of a highly innervated tissue. In some embodiments, the method includes regulating the release of the neurotrophin and the inhibitor of degradation over time. In some embodiments, the method includes monitoring the concentration of the neurotrophin over time. The system may include a device or multiple devices for the release of the neurotrophin and the inhibitor as well as a controller. In some embodiments the system may include a sensor device and/or an imaging device capable of detecting the concentration of the neurotrophin over time. The release of the neurotrophin and inhibitor of degradation may be part of a controlled release system and regulated over time.
CA2611917A1	Injection	In the case of storing and supplying an injection containing a 2-[(2-pyridyl)methylsulfinyl]benzimidazole type compound in a plastic container in addition to a glass container, an injection having been improved in stability and solubility and showing excellent qualities without forming any insoluble foreign matters or insoluble microparticles can be obtained by using cyclodextrin or its derivative together.
CA2613911A1	Crystalline forms of macrolide compounds endowed with antiinflammatory activity	The present invention relates to macrolide compounds endowed with antiinflammatory activity and more particularly relates to new stable crystalline forms of a macrolide derivative with antiinflammatory activity, processes for the preparation of such forms, pharmaceutical compositions containing them as active ingredient and the use of said crystalline Forms for the treatment of inflammatory diseases.
CA2615112A1	Synthesis and complete stereochemical assignment of psymberin/irciniastatin for anti-tumor use	The invention relates to the synthesis and complete stereochemical assignments of cytotoxic compounds such as compound 28-a and its stereoisomers. The invention further provides processes for making the compounds, their synthetic intermediates, and for methods of using the compounds and their pharmaceutical compositions for the treatment of neoplastic diseases.
CA2618638C	Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas	Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be used in combination with a therapeutic agent or may be linked to a therapeutic agent. Pseudomonas bacteria may be inhibited by blocking colonization, inhibiting virulence factors, arresting growth or killing the bacteria.
CA2624220A1	1- (1h- indol- 1-yl) -3- (methylamino) -1- phenylpropan-2-ol derivatives and related compounds as modulators of the monoamine reuptake for the treatment of vasomotor symptoms (vms)	The present invention is directed to phenylaminopropanol derivatives of formulae (I), (II), and (III); or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof.
CA2631724C	Improved oral compositions comprising zinc citrate and/or tocopherol agents	Methods and oral compositions for reducing one or more of plaque, tartar/ caries, dentinal sensitivity, malodor, and/ or inflammation are provided. The composition comprise an active ingredient that comprises a zinc salt.
CA2633296A1	Method of detecting and reducing boar taint using nuclear receptors	A method for preventing or reducing boar taint, a method of screening pigs to determine those more likely to have reduced boar taint and a method for screening substances that enhance skatole metabolism or androstenone in a pig, are disclosed These methods involve the use of the nuclear receptors constitutive androstane receptor, pregnane X receptor and farnesoid X receptor, which have been found to modulate the activity of the enzymes involved in skatole and/or androsterone metabolism
CA2635375A1	Synergistic effect between a cyanogenic system and another oxidative inducer for the treatment of tumours	The invention relates to a system which can kill tumour cells by means of caspase-independent apoptosis activation, consisting of: I. a cyanogenic system comprising the enzymatic activity exerted by linamarase on linamarin and an oxidative stress-inducing system comprising the oxidative activity of the enzyme glucose oxidase, which are combined in one composition; or II. a cyanogenic system comprising the enzymatic activity exerted by linamarase on linamarin and an oxidative stress-inducing system comprising the oxidative activity exerted by the enzyme glucose oxidase, which are present in independent compositions.
CA2635777A1	Combination therapy for diabetes	Disclosed is a pancreas-protective agent comprising a combination of a non-insulin-secreting hypoglycemic agent with a compound represented by the formula (I) or a salt thereof or a compound represented by the formula (II) or a salt thereof. (I) wherein each symbol is as defined in the description; and (II) wherein each symbol is as defined in the description.
CA2641871A1	Pharmaceutical composition for treating alcohol-induced liver injury comprising (4s, 5s)-5-fluoromethyl-5-hydroxy-4-({[(5r)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydro-5-isoxazolyl]carbonyl}amino)-dihydrofuran-2-one or pharmaceutically acceptable salt thereof	The present invention relates to a pharmaceutical composition for treating alcohol-induced liver injury comprising (4S,5S)-5-fluoromethyl-5-hydroxy-4-({[(5R)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydro-5-isoxazolyl]carbonyl}amino)-dihydrofuran-2-one or pharmaceutically acceptable salt thereof, and a use thereof.
CA2644356A1	Heterocyclic organic compounds for the treatment of in particular melanoma	The present invention relates to the discovery that certain compounds inhibit, regulate and/or modulate tyrosine and serine/threonine kinase and kinase-like proteins, such as RAF kinase, a serine/threonine kinase that functions in the MAP kinase signaling pathway, and is concerned with compositions which contain these compounds, and methods of using them to treat tyrosine and serine/threonine kinase and kinase-like dependent diseases, such as angiogenesis, cancer and cardiac hypertrophy. (Formula I).
CA2658877C	Heme oxygenase inhibitors for the treatment of a microbial infection	Inhibitors of microbial heme oxygenase and their use for treatment of microbial infections and bioremediation. The inhibitors of microbial heme oxygenase are useful against a new class of antimicrobial agents to target infections that are persistently difficult to combat with the current spectrum of antimicrobial agents. Screening methods for selecting inhibitors of microbial heme oxygenase.
CA2665501A1	Methods and compositions for the treatment and prevention of bone loss	Disclosed herein are methods and compositions for the treatment and prevention of bone loss. The methods comprise providing a therapeutically effective amount of at least one chelating agent to a subject. The methods further comprise providing a therapeutically effective amount of estrogen or at least one estrogen analogue to a subject. Compositions disclosed herein for the treatment and prevention of bone loss comprise a chelator and estrogen or at least one estrogen analogue. The compositions further comprise at least one of a bisphosphonate, a selective estrogen receptor modulator, or a hormone.
CA2665717A1	Methods and compositions comprising a flightless i antagonist for modulating wound repair	The present invention relates to a method of modulating repair of a wound. The method includes modulating expression and/or activity of Flightless I in cells involved in repair of the wound.
CA2673097A1	Fused heterocyclic compound	Disclosed is a fused heterocyclic compound having tyrosine kinase inhibitory activity. Formula (I) (In the formula, R1 represents a hydrogen atom, a halogen atom, or an optionally substituted group which is bonded through a carbon atom, a nitrogen atom or an oxygen atom, R2 represents a hydrogen atom or an optionally substituted group which is bonded through a carbon atom or a sulfur atom, or alternatively R1 and R2 or R2 and R3 are respectively bonded together to form an optionally substituted ring structure; R3 represents a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or alternatively R3 is bonded with a carbon atom of ring A to form an optionally substituted ring structure; ring A represents an optionally substituted benzene ring; and ring B represents (i) an optionally substituted fused ring, or (ii) a pyridine ring having an optionally substituted carbamoyl (which pyridine ring may be further substituted).)
CA2673510C	Maleic acid monosalt of antiviral agent and pharmaceutical composition containing the same	The present invention relates to 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl} oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-3.lambda.5-phosphanon-1-yl-pivalate maleic acid monosalt, and pharmaceutical composition containing the same.
CA2675510A1	Method for decreasing inflammation and oxidative stress in mammals	The present invention is directed to a method for decreasing inflammation and oxidative stress in a mammal comprising; administration to a mammal a composition comprising a glucose antimetabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to decrease a level of an oxidized glutathione and/or increase the ration of reduced glutathione to oxidized glutathione in the blood of the mammal subsequent to administration of the glucose anti-metabolite.
CA2676172A1	Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenyl-piperidin-3s-yl-)	The present invention relates to pharmaceutical compositions comprising an NK1 receptor antagonist and a sodium channel blocker compound of formula (I) wherein R1 and R2 are independently hydrogen, C1-6alkyl or C3-6cycloalkylC1-6alkyl; or R1 and R2, together with the nitrogen to which they are attached, may form an unsubstitued 3-, 4-, 5- or 6-membered saturated ring; R3 is C1-6alkyl, C1-6haloalkyl, C1-3alkoxyC1-3alkyl or C1-3haloalkoxyC1-3alkyl; or R1 and R3, together with the interconnecting atoms, form a saturated or unsaturated 4- to 6-membered ring; X is carbon or nitrogen; n is 0, 1 or 2, wherein when present each R4 is independently selected from the list consisting of C1-3alkyl, halogen, cyano, haloC1-3alkyl, hydroxy, C1-3alkoxy and C1-3haloalkoxy; q is 1 or 2; either R5 or R6 is -O-R7 or -OCH2R7, wherein the other R5 or R6 is hydrogen or R4; and wherein R7 is either a phenyl ring or a 5- or 6-membered aromatic heterocyclic ring (independently containing one or more nitrogen, sulphur or oxygen atoms) wherein either the phenyl ring or the heterocyclic ring is optionally substituted by one or more groups independently selected from the list consisting of C1-3alkyl, halogen, cyano, haloC1-3alkyl, hydroxy, C1-3alkoxy and C1-3haloalkoxy; or a pharmaceutically acceptable salt or solvate thereof; as a combined preparation for simultaneous or sequential administration, and to the use of such compositions in the treatment of certain disorders, including epilepsy and mood disorders.
CA2679103A1	O6-alkylguanine-dna alkyltransferase inactivators	Disclosed are inactivators of O6-alkylguanine-DNA alkyltransferase (AGT) having the formula:(I) wherein R, R1 and R3 are as described herein. The inactivators are highly water soluble. Also disclosed are pharmaceutical compositions comprising an inactivator and a pharmaceutically acceptable carrier, and a method of use of the inactivator in enhancing the chemotherapeutic treatment of tumor cells in a mammal, e.g., a human, with an antineoplastic alkylating agent that causes cytotoxic lesions at the O6-position of guanine.
CA2681864A1	Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine	The present invention relates to crystalline forms of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethylamine ("COMPOUND I") useful in the treatment of RAGE mediated diseases.
CA2688736A1	Novel compositions containing lysozyme and c-1/c-4 polysaccharides and use thereof in oral care, cosmetology and dermatology, contraception, urology and gynecology	A composition comprising a content of a lysozyme and a content of a C-1/C-4 polysaccharide is useful in oral care, cosmetology and dermatology, contraception, urology and gynecology. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.
CA2691943A1	Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions	Compositions comprising: - vasokinetic natural coumarins or extracts containing them; anti-phosphodiesterase agents selected from 3,7-O-di-(2- hydroxyethyl)icaritin or 7-O-hydroxyethyl-icariside 11 and/or forskolin or extracts containing them; phytoestrogens selected from ferutinine or ferutinine- containing extracts ofFerula sp.or p-pivaloylferutinine.
CA2704882A1	Use of amorolfine for treating a nail disease by iontophoresis	The invention relates to the use of a composition comprising 1 % to 5% by weight of amorolfine in ionized form in an aqueous-alcoholic solution, at a pH of between 3 and 6, in the manufacture of a medicament for use in the treatment of a nail disease, said composition being applied to the nail in combination with an iontophoretic current, the intensity of which is between 0.01 and 5 mA/cm2, for a period of time which is sufficient to enable the amorolfine to pass into or through the nail.
